Zoetis Inc. (ZTS)

20 members of Congress have disclosed trading ZTS — 17 purchases and 17 sales worth an estimated $394,500. Most recent disclosure: Nov 18, 2025.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Company website ↗

• P/E ratio (12.5) — how many dollars you pay for each $1 of ZTS's yearly profit. That's on the low side, which can mean it's cheap — or that the market is worried.
• ROE (67.75%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
• Profit margin (28.04%) — of every $1 in sales, this is what's left as profit after all costs.
• Dividend yield (2.79%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.